Alendronate treatment for osteoporosis: A review of the clinical evidence

Osteoporosis International

Volumn 6, Issue 6, 1996, Pages 419-426

  Selby, P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alendronate; Bisphosphonates; Bone mineral density; Femoral fracture; Osteoporosis treatment; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; DOSE RESPONSE; FEMALE; FEMUR FRACTURE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; REVIEW; VERTEBRA FRACTURE;

ALENDRONATE; BONE DENSITY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SAFETY; TREATMENT OUTCOME;

EID: 0030457851     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01629572     Document Type: Review

References (47)

1. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 1991;42:919-44.
2. Kanis JA, Gertz BJ, Singer F, Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int 1995;5:1-13.
3. Shinoda A, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
4. Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective tissue cells in culture. Biochem J 1978;172:97-107.
5. 14C-1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 1984;36:108-13.
6. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984;1:821-4.
7. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. BMJ 1986;292:1227-9
8. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
9. Lin JH, Duggan DE, Chen I-W, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Disposit 1991;19:926-32.
10. Gertz BJ, Kline WF, Matuszeswki BK, Sacco JF, Lasseter KC, Porras AG. Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidine bisphosphonate) in postmenopausal women [abstract]. J Bone Miner Res 1991;6(Suppl 1):S281.
11. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
12. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76:1399-406.
13. Frost HM. Bone remodelling and its relationship to metabolic bone disease. Springfield, IL: CC Thomas, 1973.
14. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994;9:1833-7.
15. Pedrazonni M, Palummeri E, Ciotti G, Davoli L, Pioli G, Girasole G, et al. Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone. Bone Miner 1989;7:301-7.
16. O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NAT, Beneton MNC, Harris S, et al. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 1990;5:483-91.
17. O'Doherty DP, Bickerstaff DR, McCloskey EV, Eyres KS, Kanis JA. Radiographic healing of osteolytic Paget's disease of the tibia with alendronate. J Orthop Rheumatol 1991;4:153-7.
18. O'Doherty DP, Gertz BJ, Tindale W, Sciberras DG, Survill TT, Kanis JA. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. J Bone Miner Res 1992;7:81-7.
19. Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, Bertoldo F, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone Bone 1994;15:415-7.
20. Adami S, Bolzicco GP, Rizzo A, Salvagno G, Bertoldo F, Rossini M, et al. The use of dichlormethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner 1987;2:395-404.
21. Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis: comparison with dichloromethylene diphosphonate. Arch Intern Med 1987; 147:1629-33.
22. Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NAT, Main M, Kanis JA. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. Bone 1991;12:17-20.
23. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 1992;50:706-12.
24. Zysset E, Ammann P, Jenzer A, Gertz BJ, Portmann L, Rizzoli R, et al. Comparison of a rapid (2-h) versus a slow (23-h) infusion of alendronate in the treatment of the hypercalcemia of malignancy. Bone Miner 1992;18:237-49.
25. Nussbaum SR, Warrell RP, Rude R, Glusman J, Bilezikian JP, Stewart AF, et al. A dose response study of alendronate sodium for the treatment of cancer associated hypercalcemia. J Clin Oncol 1993;11:1618-23.
26. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993;11:1618-23.
27. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
28. Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int 1993;3(Suppl 3):S21-7.
29. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple doses on bone mass remodelling. Am J Med 1995;99:144-52.
30. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N End J Med 1995;333:1437-43.
31. Dechant KL, Goa KL. Calcitnol: a review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drugs Aging 1994;5:300-17.
32. Devogelaer JP, Broll J, Correarotter R, Cumming DC, de Deuxchaines CN, Geusens P, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip and total body over three years in postmenopausal women with osteoporosis. Bone 1996;18:141-50.
33. Weinstein RS, Bone H, Tucci J, Downs R, Harris S, Licata A, et al. Alendronate treatment of osteoporosis in elderly women [abstract]. J Bone Miner Res 1994;9(Suppl 1):S144.
34. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbargallo M, Costi D, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991;15:237-48.
35. Parfitt AM. Morphological basis of bone minral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 1980;4:273-87.
36. Valkema R, Vismans FJ, Papapoulos SE, Pauwels EK, Bijvoet OL. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989;5:183-92.
37. Devogelaer JP, Nagant de Deuxchaines C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): non-linear increase of lumbar bone mineral density. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress 1990:1507-9.
38. Howard T, Kimmel D, Recker R, Bone H, Bankhurst A, Barrett J, et al. Mineralization and turnover of bone in elderly women with osteoporosis treated with oral alendronate [abstract]. J Bone Miner Res 1995;1(Suppl 1):S197.
39. Arlot MC, Meunier PJ, Chavassieux P, Recker R, Reda C, Wei L, et al. Effects of long term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry [abstract]. J Bone Miner Res 1995;10(Suppl 1):S199.
40. Parfitt AM, Kleerekoper M, Villenueva AR. Increased bone age: mechanisms and consequences. In: Christiansen C, Johansen JS, Riis BJ. editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987;301-8.
41. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clincially diagnosed vertebral fracturs: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992;7:221-7.
42. Shapiro DR, Thompson DE, Karpf DB, Santora AC, Lombardi A, Hirsch LJ, et al. Non-vertebral fracture incidence in patients treated with alendronate [abstract]. J Bone Miner Res 1995;10(Suppl 1):S176.
43. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporosis Int 1993;3(Suppl 3):S29-3.
44. Devogelaer JP, Nagrant de Deuxchaines C. Treatment of involutional osteoporosis with the bisphosphonate (ADP) (disodium pamidronate): non-linear increases of lumbar bone mineral density [abstract]. J Bone Miner Res 1990;5(Suppl 2):S261.
45. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36-42.
46. Rehman MTA. The role of histomorphometry in the management of postmenopausal osteoporosis [thesis]. University of Manchester, 1994.
47. Selby PL. Calcium requirement: a reappraisal of the methods used in its determination and their application to patients with osteoporosis. Am J Clin Nutr 1994;60:944-8.